Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: normal saline 0.9% Clear all
Completed Phase 4 Interventional Results available

Ultrasound-guided Adductor Canal Block for Total Knee Replacement

NCT02100579
View directory record Official record
Conditions
Complications; Arthroplasty, Knee Injuries
Interventions
Bupivacaine, Preservative free normal saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Isotonic Solution Administration Logistical Testing

NCT02345486
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
0.9% sodium chloride, Physiologically balanced fluid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 7, 2026, 10:27 AM EDT
Terminated Phase 4 Interventional Results available

Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis

NCT01234883
View directory record Official record
Conditions
Dehydration, Gastroenteritis
Interventions
multiple electrolyte solution, saline
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
6 Months to 10 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 7, 2026, 10:27 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of VIS649 for IgA Nephropathy

NCT04287985
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions
Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

NCT00238433
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

NCT01813058
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403
View directory record Official record
Conditions
Healthy
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

NCT01060670
View directory record Official record
Conditions
Neuropathic Diabetic Ulcer - Foot
Interventions
Integra® Dermal Regeneration Template, Conventional Wound Therapy
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
32
States / cities
Mobile, Alabama • Bakersfield, California • Castro Valley, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 7, 2026, 10:27 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Intravenous Tranexamic Acid During Rhytidectomy

NCT03970213
View directory record Official record
Conditions
Bleeding, Bruising Face, Swelling Lips & Face
Interventions
Tranexamic Acid 100Mg/Ml Inj Vil 10Ml, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Glasgold Group Plastic Surgery
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

NCT02742103
View directory record Official record
Conditions
Acute Myocardial Infarction, Moderate Renal Impairment
Interventions
CSL_112, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

NCT01340547
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
palifosfamide-tris, Normal Saline
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Dallas, Texas • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Solution Temperature and Fluid Deficit During Hysteroscopy

NCT05622097
View directory record Official record
Conditions
Surgery
Interventions
0.9% Saline warmed to 37 degrees Celsius, 0.9% Saline warmed to 24 degrees Celsius
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 7, 2026, 10:27 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO

NCT03823417
View directory record Official record
Conditions
Bleeding
Interventions
Tranexamic Acid, Normal saline
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 7, 2026, 10:27 AM EDT
Terminated Phase 3 Interventional Results available

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

NCT00316004
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
7.5% Hypertonic Saline in 6% Dextran-70 (HSD), 7.5% Hypertonic Saline (HS), 0.9% Normal Saline (NS)
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 7, 2026, 10:27 AM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

NCT01507233
View directory record Official record
Conditions
Bowel Obstruction
Interventions
IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

NCT00700336
View directory record Official record
Conditions
Malignant Pleural Mesothelioma, Solid Tumors
Interventions
pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding
Drug
Lead sponsor
CanBas Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

NCT04238793
View directory record Official record
Conditions
Neuropathic Pain From Lumbosacral Radiculopathy
Interventions
KLS-2031, Placebo
Drug · Other
Lead sponsor
Kolon Life Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

NCT07473752
View directory record Official record
Conditions
Phase 1 First-in-human Study Involving Healthy Subjects
Interventions
TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH)
Drug · Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis

NCT02576249
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ropivacaine, Normal saline, Methylprednisolone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Results available

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

NCT03873987
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Current Formulation of Oritavancin, Kimyrsa
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Burr Ridge, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

NCT03867084
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
24
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184
View directory record Official record
Conditions
COVID-19
Interventions
Crizanlizumab, 0.9% saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 7, 2026, 10:27 AM EDT